ADH-1, an antagonist of N-cadherin, blocks N-cadherin-mediated cell adhesion. It exhibits significant antitumor activity against N-cadherin-expressing cells in vitro assays.

ADH-1, an antagonist of N-cadherin, blocks N-cadherin-mediated cell adhesion. It exhibits significant antitumor activity against N-cadherin-expressing cells in vitro assays.

Etanercept, a dimeric fusion protein, functions as an inhibitor of TNF by binding to TNF. It competitively blocks the attachment of both TNF-α and TNF-β to their cell surface receptors, thereby neutralizing TNF’s biological activity. Etanercept has proven effectiveness in treating rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.

ADH-1, an antagonist of N-cadherin, blocks N-cadherin-mediated cell adhesion. It exhibits significant antitumor activity against N-cadherin-expressing cells in vitro assays.

SN52, a cell-permeable peptide containing the p50 NLS, is a selective inhibitor of NF-κB pathway. It selectively and completely blocks the ionizing radiation (IR)-induced nuclear import of p52 and RelB. It also enhances the radiosensitivity of prostate cancer cells.

SN52, a cell-permeable peptide containing the p50 NLS, is a selective inhibitor of NF-κB pathway. It selectively and completely blocks the ionizing radiation (IR)-induced nuclear import of p52 and RelB. It also enhances the radiosensitivity of prostate cancer cells.

ADH-1, an antagonist of N-cadherin, blocks N-cadherin-mediated cell adhesion. It exhibits significant antitumor activity against N-cadherin-expressing cells in vitro assays.

SN52, a cell-permeable peptide containing the p50 NLS, is a selective inhibitor of NF-κB pathway. It selectively and completely blocks the ionizing radiation (IR)-induced nuclear import of p52 and RelB. It also enhances the radiosensitivity of prostate cancer cells.

SN52, a cell-permeable peptide containing the p50 NLS, is a selective inhibitor of NF-κB pathway. It selectively and completely blocks the ionizing radiation (IR)-induced nuclear import of p52 and RelB. It also enhances the radiosensitivity of prostate cancer cells.

Anakinra (Raleukin, AMG-719) is an exogenous antagonist of recombinant human interleukin-1 receptor that also inhibits caspase-1 and caspase-9 activity with Ki of 0.201 μM and 0.31 μM respectively. It is used in research to study IL-1 blockade in inflammation, tumor growth, islet transplantation, and cardiac injury models.